SEZARY SYNDROME
Clinical trials for SEZARY SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SEZARY SYNDROME trials appear
Sign up with your email to follow new studies for SEZARY SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists probe blood Treatment's power against rare cancer
Disease control Recruiting nowThis study is testing if a standard blood treatment called Extracorporeal Photopheresis (ECP) can help the body's immune system fight Sezary Syndrome, a rare and aggressive form of skin lymphoma. It will enroll 20 patients to receive ECP for about 6 months. The main goal is to se…
Matched conditions: SEZARY SYNDROME
Sponsor: Oleg E. Akilov, MD, PhD • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Could a gentler dose fight skin cancer just as well?
Disease control Recruiting nowThis study is testing whether a lower dose of the cancer drug brentuximab vedotin can effectively treat certain types of skin lymphoma while potentially causing fewer side effects. It is enrolling adults with mycosis fungoides, Sezary syndrome, or lymphomatoid papulosis who need …
Matched conditions: SEZARY SYNDROME
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Double attack on devastating skin cancer
Disease control Recruiting nowThis study is testing a two-part treatment for a severe, widespread red rash caused by a rare skin cancer called cutaneous T-cell lymphoma (CTCL). It combines a drug (mogamulizumab) that targets cancer cells with a blood treatment (ECP) that aims to boost the immune system. The g…
Matched conditions: SEZARY SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Post-Approval watch: tracking a rare cancer Drug's Real-World performance
Disease control Recruiting nowThis study is monitoring how safe and effective the drug Poteligeo (mogamulizumab) is for patients in Korea who are already using it to treat two rare types of skin lymphoma. It will follow about 15 adult patients who have tried at least one other treatment before. The goal is to…
Matched conditions: SEZARY SYNDROME
Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Scientists seek clues in blood and skin to fight itchy, serious rashes
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, and skin samples from adults with specific skin conditions like cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The purpose is to build a collection of samples for researchers to study. By analyzing these samples, scientists hope …
Matched conditions: SEZARY SYNDROME
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:18 UTC